Lassa hemorrhagic shock syndrome-on-a-chip

Area of Science:

• Biomedical Engineering
• Infectious Diseases
• Vascular Biology

Background:

• Lassa hemorrhagic fever research is limited by the lack of suitable experimental human models.
• Developing effective treatment strategies requires better in vitro systems to study disease pathogenesis.
• Current models do not fully replicate the complex vascular interactions seen in Lassa hemorrhagic fever.

Purpose of the Study:

• To develop and validate the first chip-based model for Lassa hemorrhagic syndrome.
• To quantitatively assess vascular integrity changes in response to Lassa virus-like particles.
• To evaluate the therapeutic potential of FX06 in mitigating vascular damage.

Main Methods:

• A microvessel-interfacing collagen network chip was engineered to mimic the extracellular matrix.
• Lassa virus-like particles were infused to assess their impact on vascular permeability.
• Vascular integrity was quantitatively measured in real-time.
• The efficacy of Fibrin-derived peptide FX06 in preventing vascular leakage was tested.

Main Results:

• The chip model successfully mimicked key aspects of Lassa hemorrhagic syndrome.
• Lassa virus-like particles induced a dose-dependent increase in vascular permeability.
• Fibrin-derived peptide FX06 demonstrated a significant ability to suppress vascular integrity loss.
• The model allowed for real-time assessment of disease progression and therapeutic intervention.

Conclusions:

• The developed chip-based model offers a promising human-like experimental system for Lassa hemorrhagic fever research.
• This platform facilitates the assessment of disease severity and the investigation of Lassa pathogenesis.
• It provides a valuable tool for high-throughput drug screening and development for Lassa virus infections.